Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) (Q35976515)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) |
scientific article |
Statements
1 reference
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) (English)
1 reference
John E Gerich
1 reference
Vivian A Fonseca
1 reference
Ricardo Alvarado-Ruiz
1 reference
Denis Raccah
1 reference
Gabor Boka
1 reference
Patrick Miossec
1 reference
EFC6018 GetGoal-Mono Study Investigators
1 reference
1 reference
Identifiers
1 reference